NCT/Study#

P153CV-RAS-001

Phase I study dose finding study to evaluate safety, reactogenicity and immunogenicity of CV09040102 RAS G12D mRNA vaccine in HLA- selected patients with pancreatic cancer or colorectal cancer harboring the RAS G12D mutation

Phase I study dose finding study to evaluate safety, reactogenicity and immunogenicity of CV09040102 RAS G12D mRNA vaccine in HLA- selected patients with pancreatic cancer or colorectal cancer harboring the RAS G12D mutation

DISEASE GROUP:
Phase 1
current phase:
Phase I
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: